NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its third quarter revenues rose 18 percent, driven by the company's molecular business, which now includes Nanosphere.

For the quarter ended Sept. 30, the molecular diagnostics company reported revenues of $71.2 million, up from $60.6 million in the year-ago quarter, and beating the average Wall Street estimate for revenues of $68.6 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.